<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704115</url>
  </required_header>
  <id_info>
    <org_study_id>2019_43</org_study_id>
    <secondary_id>2020-A02354-35</secondary_id>
    <nct_id>NCT04704115</nct_id>
  </id_info>
  <brief_title>The Therapy of Large Endometrioma</brief_title>
  <acronym>ENDOKYSTE</acronym>
  <official_title>Evaluate the Therapy of Large Ovarian Endometrioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometrioma's prevalence is between 23 and 55%. It causes pelvic pain, decrease fertility&#xD;
      and ovarian reserve.&#xD;
&#xD;
      Currently, there's no recommendation about large endometrioma's treatment and there's no&#xD;
      information on the best treatment to limit recurrences, preserve fertility and ovarian&#xD;
      reserve.&#xD;
&#xD;
      In Lille university hospital, simple laparoscopic drainage associated with hormonal therapy&#xD;
      is practiced to reduce the risk of cystectomy.&#xD;
&#xD;
      This protocol will be evaluated with an observational and prospective study, including women&#xD;
      of childbearing age having endometrioma measuring 6 cm or above.&#xD;
&#xD;
      The aim of this study is to assess if cyst drainage associated with GnRH agonist, could&#xD;
      decrease endometrioma recurrences, deleterious effect on ovarian reserve and evaluate impact&#xD;
      on anti-mullerian hormone&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Recurrence of cyst ≥ 3 cm determined by MRI or pelvic ultrasonography (US)</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The impact of the ovarian reserve postoperative</measure>
    <time_frame>at 3 months</time_frame>
    <description>Compare the dosages of anti-mullerian hormone (AMH) preoperative and postoperative at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of re-operation</measure>
    <time_frame>at 4 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Endometrioma</condition>
  <condition>Endometriosis Ovary</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Women presenting at a surgical consultation for the management of an endometrioma of 6cm or&#xD;
        more&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Endometrioma size ≥ 6cm determined by MRI or ultrasonography&#xD;
&#xD;
          -  Women with isolated endometrioma or other extraovarian endometriosis: peritoneal,&#xD;
             infiltrating endometriotic lesions and adenomyosis.&#xD;
&#xD;
          -  Cyst single or bilateral&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cyst with radiographic or macroscopic in laparoscopy atypia&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patient with contraindication to GnRH agonist (Enantone® 3,75 mg et Decapeptyl® 3 mg)&#xD;
&#xD;
          -  Patient with contraindication to laparoscopy&#xD;
&#xD;
          -  Patient with contraindication to general anesthesia&#xD;
&#xD;
          -  Subject refusing to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chrytèle RUBOD, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chrytèle RUBOD, MD,PhD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>chrystele.rubod@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hop Jeanne de Flandre Chu Lille</name>
      <address>
        <city>Lisle-sur-Tarn</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0320445962</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometriomas measuring 6 cm or more</keyword>
  <keyword>Ovarian Endometrioma</keyword>
  <keyword>laparoscopic drainage</keyword>
  <keyword>recurrence</keyword>
  <keyword>AMH</keyword>
  <keyword>GnRH agonist therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

